| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 36,580 | $30 | $1.2M |
| J0897 | Injection, denosumab, 1 mg | 29,700 | $20 | $534.6K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 8,210 | $30 | $213.5K |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 50,800 | $1 | $203.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,300 | $90 | $120K |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 14,280 | $10 | $114.2K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 690 | $60 | $37.9K |
| 99205 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider… | 180 | $160 | $28.4K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 520 | $50 | $24.8K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 400 | $60 | $24.7K |